CD56 and PGP expression in acute myeloid leukemia: Impact on clinical outcome

Haematologica

Volumn 87, Issue 11, 2002, Pages 1135-1140

  Raspadori, Donatella ^a,d   Damiani, Daniela ^a   Michieli, Mariagrazia ^c   Stocchi, Raffaella ^b   Gentili, Sara ^a   Gozzetti, Alessandro ^a   Masolini, Paola ^b   Michelutti, Angela ^b   Geromin, Antonella ^b   Fanin, Renato ^b   Lauria, Francesco ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d Ospedale A Sclavo   (Italy)

Author keywords

AML; CD56; Complete remission; MDR; PGP

Indexed keywords

CD56 ANTIGEN; CYTARABINE; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANTIGEN DETECTION; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA CELL; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD56; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 6444245006     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Tsuruo T. Mechanism of multidrug resistance and implications for therapy. Jpn J Cancer Res 1988; 79:285-96.
2. Gottesman MM, Pastan I. Resistance to multiple chemotherapeutic agents in human cancer cells. Trends Pharmacol Sci 1988; 9:54-8.
3. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80:2735-9.
4. Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 1989; 9:3808-20.
5. Weinstein RS, Kuszak JR, Kluskens LF, Coon JS. P-glycoproteins in pathology: The multidrug resistance gene family in humans. Hum Pathol 1990; 21:34-48.
6. Michieli M, Damiani D, Geromin A, Michelutti A, Fanin R, Raspadori D, et al. Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia. Eur J Haematol 1992; 48:87-92.
7. Zochbauer S, Gsur A, Brunner R, Kyrle PA, Lechner K, Pirker R. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 1994; 8:974-7.
8. Del Poeta G, Stasi R, Aronica G, Venditti A, Cox MC, Bruno A, et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 1996; 87:1997-2004.
9. Michieli M, Damiani D, Ermacora A, Raspadori D, Michelutti A, Grimaz S, et al. P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells. Br J Haematol 1997; 96:356-65.
10. Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21) (q22;q22). Blood 1997; 90:1643-8.
11. + t(8;21) AML blasts: Further suggestion of the adverse clinical significance of this biological marker? Br J Haematol 1999; 107:381-3.
12. Murray CK, Estey E, Paietta E, Howard RS, Edenfield WJ, Pierce S, et al. CD56 expression in acute promyelocytic leukemia: A possible indicator of poor treatment outcome? J Clin Oncol 1999; 17:293-7.
13. Ferrara F, Morabito F, Martino B, Specchia G, Liso V, Nobile F, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol 2000; 18:1295-300.
14. Raspadori D, Damiani D, Lenoci M, Rondelli D, Testoni N, Nardi G, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 2001; 15:1161-4.
15. Ciolli S, Leoni F, Nozzoli C, Longo G, Gianfaldoni G, Caporale R, et al. Prognostic impact of CD56 in 141 cases of acute myeloid leukemia. Haematologica 2001; Suppl 10: 86:a17[abstract].
16. Di Bona E, Sartori R, Zambello R, Guercini N, Madeo D, Rodeghiero F. Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica 2002; 87:250-6.
17. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33:451-8.
18. Mitelman F. An International System for Human Cytogenetic Nomenclature. Basel; S. Karger: 1995.
19. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, et al. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89:3323-9.
20. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996; 87:2464-9.
21. Izquierdo MA, Scheffer GL, Flens MJ, Schroeijers AB, van der Valk P, Scheper RJ. Major vault protein LRP-related multidrug resistance. Eur J Cancer 1996; 32A:979-84.
22. Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jager U, et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998; 91:1508-13.
23. Michieli M, Damiani D, Ermacora A, Masolini P, Raspadori D, Visani G, et al. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: Biological and clinical implications. Br J Haematol 1999; 104:328-35.
24. Legrand O, Zittoun R, Marie JP. Role of MRP1 in multidrug resistance in acute myeloid leukemia. Leukemia 1999; 13:578-84.
25. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group study. Blood 1999; 94:1086-99.
26. Damiani D, Michieli M, Ermacora A, Candoni A, Raspadori D, Geromin A, et al. P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias. Haematologica 1998; 83:290-7.
27. Dastugue N, Payen C, Lafage-Pochitaloff M, Bernard P, Leroux D, Huguet-Rigal F, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia 1995; 9:1491-8.
28. Raspadori D, Lauria F, Ventura MA, Rondelli D, Visani G, de Vivo A, et al. Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: Analysis of 141 cases. Leuk Res 1997; 21:603-7.
29. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986; 136:4480-6.
30. Griffin JD, Hercend T, Beveridge R, Schossmann SF. Characterization of an antigen expressed by human natural killer cells. J Immunol 1983; 130:2947-51.
31. Lanier LL, Testi R, Bindi J, Phillips JH. Identity of Leu-19 (CD56) leucocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 1989; 169:2233-8.
32. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992; 80:2729-34.
33. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83:2451-8.
34. Johnston RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 2000; 25:1-6.
35. + hematopoietic stem cells. Haematologica 2002; 87:564-8.